A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: A Phase I study in Japan

International Journal of Hematology

Volumn 88, Issue 1, 2008, Pages 73-81

  Miyazawa, Keisuke ^a   Ohyashiki, Kazuma ^a   Urabe, Akio ^b   Hata, Tomoko ^c   Nakao, Shinji ^d   Ozawa, Keiya ^e   Ishikawa, Takayuki ^f   Kato, Junji ^g   Tatsumi, Yoichi ^h   Mori, Hiraku ⁱ   Kondo, Midori ^j   Taniguchi, Junsuke ^j   Tanii, Hiromi ^j   Rojkjaer, Lisa ^k   Omine, Mitsuhiro ⁱ  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Kanto Teishin Hospital   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g SAPPORO MEDICAL UNIVERSITY   (Japan)

^h KINKI UNIVERSITY   (Japan)

ⁱ SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^j NOVARTIS PHARMA K K   (Japan)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Deferasirox; Iron chelation; Iron overload; Myelodysplastic syndrome

Indexed keywords

DEFERASIROX; DEFEROXAMINE MESYLATE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; BETA THALASSEMIA; BLOOD TRANSFUSION; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DEMENTIA; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; EXCRETION; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HUMAN; INTERSTITIAL NEPHRITIS; IRON BALANCE; IRON OVERLOAD; JAPANESE; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; PHARYNX DISEASE; PHARYNX ULCER; PHASE 1 CLINICAL TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN URINE LEVEL; RASH; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOIC ACIDS; BLOOD TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; JAPAN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRIAZOLES;

EID: 56749134190     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0115-2     Document Type: Article

References (21)

1. N Olivieri 1998 Thalassaemia: clinical management Baillieres Clin Haematol 11 147 62
2. AJ Jansen ML Essink-Bot EA Beckers WC Hop MR Schipperus DJ Van Rhenen 2003 Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes Br J Haematol 121 270 4
3. MT Lee S Piomelli S Granger 2006 Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results Blood 108 847 52
4. GD McLaren WA Muir RW Kellermeyer 1983 Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy Crit Rev Clin Lab Sci 19 205 66
5. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001;47-61.
6. V Gabutti A Piga 1996 Results of long-term iron-chelating therapy Acta Haematol 95 26 36
7. NF Olivieri DG Nathan JH MacMillan 1994 Survival in medically treated patients with homozygous β-thalassemia N Engl J Med 331 574 8
8. NF Olivieri GM Brittenham 1997 Iron-chelating therapy and the treatment of thalassemia Blood 89 739 61
9. A Cortelezzi C Cattaneo S Cristiani 2000 Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J 1 153 8
10. JB Porter RD Abeysinghe L Marshall RC Hider S Singh 1996 Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy Blood 88 705 13
11. ZI Cabantchik W Breuer G Zanninelli P Cianciulli 2005 LPI-labile plasma iron in iron overload Best Pract Res Clin Haematol 18 277 87
12. M Takatoku T Uchiyama S Okamoto 2007 Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality Eur J Haematol 78 487 94
13. N Gattermann JB Porter LF Lopes J Seymour 2005 Iron overload in myelodysplastic syndromes Hematol Oncol Clin North Am 19 Suppl 1 18 25
14. A Piga R Galanello GL Forni 2006 Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload Haematologica 91 873 80
15. J Porter R Galanello G Saglio 2008 Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study Eur J Haematol 80 168 76
16. MD Cappellini A Cohen A Piga 2006 A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia Blood 107 3455 62
17. E Vichinsky O Onyekwere J Porter 2007 A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease Br J Haematol 136 501 8
18. R Galanello A Piga GL Forni 2006 Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major Haematologica 91 1343 51
19. E Nisbet-Brown NF Olivieri PJ Giardina 2003 Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 361 1597 602
20. Piga A, Galanello R, Cappellini MD, et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood. 2003;102: abstr 412.
21. E Vichinsky 2008 Clinical application of deferasirox: practical patient management Am J Hematol 83 398 402